Abstract: The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4 carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y12 receptor antagonist.
Type:
Grant
Filed:
September 21, 2017
Date of Patent:
August 4, 2020
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Daniel Leuenberger, Stefan Reber, Markus Von Raumer
Abstract: The dosing apparatus comprises a conveying device (5), which is driven by at least one conveying drive (4), for conveying fluid from the interior (3) of a container (2). The fluid by means of the conveying device (5) is conveyable from the container to a dispensing opening (6). The conveying device (5) comprises a cylinder (7) having at least one intake opening (11) and at least one outlet opening (12) on an inner cylinder wall (8), and a first piston (9) and a second piston (10). The first piston (9) and the second piston (10) are mounted within the cylinder (7) so as to be displaceable in the longitudinal direction. Furthermore, the first piston (9) and the second piston (10) between the end sides thereof and together with a portion of the inner cylinder wall (8) delimit a variable fluid volume (17).
Abstract: The invention relates to aryloxazolidinone compounds of formula I: wherein Y represents hydrogen or certain chemical groups. These compounds are useful antimicrobial agents effective against a variety of pathogens including inter alia Gram-negative aerobic and anaerobic bacteria.
Type:
Grant
Filed:
February 16, 2018
Date of Patent:
April 28, 2020
Assignee:
Idorsia Pharmaceuticals Ltd.
Inventors:
Daniel Ritz, Georg Rueedi, Cornelia Zumbrunn
Abstract: The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4 carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y12 receptor antagonist.
Type:
Application
Filed:
September 21, 2017
Publication date:
January 16, 2020
Applicant:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Daniel LEUENBERGER, Stefan REBER, Markus VON RAUMER
Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
Abstract: The invention relates to antibacterial compounds of formula I wherein M is one of the groups MA, MB and MC represented below and either R1 represents H and R2 represents a cleavable group as defined in the claims or R2 represents H and R1 represents a cleavable group as defined in the claims; and salts thereof.
Type:
Grant
Filed:
August 10, 2016
Date of Patent:
October 15, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD.
Inventors:
Stefan Diethelm, Philippe Panchaud, Georg Rueedi, Jean-Luc Specklin, Jean-Philippe Surivet
Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
Type:
Application
Filed:
May 7, 2019
Publication date:
August 29, 2019
Applicant:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi Williams
Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
July 16, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist, Markus Von Raumer
Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
June 25, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
Abstract: The invention relates to antibacterial compounds of formula I wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.
Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
May 28, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
Abstract: The invention relates to compounds of Formula (I) wherein X, Y, R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.
Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
Type:
Grant
Filed:
September 14, 2015
Date of Patent:
April 2, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Olivier Bezencon, John Gatfield, Bibia Heidmann, Romain Siegrist, Simon Stamm
Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
Type:
Application
Filed:
September 14, 2016
Publication date:
February 14, 2019
Applicant:
Idorsia Pharmaceuticals Ltd.
Inventors:
Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST, Markus VON RAUMER
Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
February 12, 2019
Assignee:
IDORSIA PHARMACEUTICALS LTD.
Inventors:
Philippe Guerry, Francois Lehembre, Julien Pothier, Hervé Siendt
Abstract: The invention relates to antibacterial compounds of formula I wherein X represents sulphur or CH?CH; R1 represents H, PO3H2, SO3H, phosphonooxymethyl or the group —CO—R2 wherein R2 is as defined in the claims M is one of the groups MA and MB represented below wherein A represents a bond or C?C and R1A, R2A, R3A and R1B are as defined in the claims; and to salts thereof.
Type:
Application
Filed:
August 26, 2016
Publication date:
January 31, 2019
Applicant:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Philippe PANCHAUD, Christine SCHMITT, Jean-Philippe SURIVET
Abstract: The invention relates to antibacterial compounds of formula I wherein R1 is one of the groups represented below wherein A is a bond, CH?CH or C?C; U is N or CH; V is N or CH; W represents N or CH; and R1A, R2A, R3A, R1B and R1C are as defined in the claims; and salts thereof.
Abstract: The invention relates to antibacterial compounds of formula I wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.
Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
Type:
Grant
Filed:
December 19, 2017
Date of Patent:
September 4, 2018
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon